0001088856false00010888562025-06-102025-06-10

June 10, 2025

Date of Report (date of earliest event reported)

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

On June 10, 2025, Corcept Therapeutics Incorporated (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”) to consider and vote on the following proposals: 1) to elect nine directors to hold office until its 2026 annual meeting of stockholders and until their successors are duly elected and qualified, 2) to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, and 3) to approve, on an advisory basis, the compensation of the Company's named executive officers.

A total of 106,044,683 shares of the Company's common stock held by stockholders of record at the close of business on April 17, 2025 were entitled to vote at the Annual Meeting. The total number of shares voted at the Annual Meeting was 92,327,139. The voting on the three matters is set forth below:

Proposal 1 - Election of Directors. The following directors were elected to serve until the Company's 2026 annual meeting of stockholders.

Proposal 2 - The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified.

Proposal 3 - The compensation of named executive officers was approved, on an advisory basis.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.